U.S. Markets closed

Advanced Medical Isotope Corporation Appoints Dr. Alice Villalobos Chair of the Veterinary Medicine Advisory Board

KENNEWICK, WA / ACCESSWIRE / March 14, 2016 / Advanced Medical Isotope Corporation (or "AMI") (ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today announced that Dr. Alice Villalobos, DVM, FNAP, a specialist and advocate on the topic of cancer in pets, has been appointed Chair of the Company's Veterinary Medicine Advisory Board.

AMI has been actively seeking partnerships to bring its yttrium-90 brachytherapy products to the veterinary markets. Pets are integrated members of the family in many homes, with an estimated 150,000,000 pet cats and dogs in America. Appointing Dr. Alice to chair AMI’s new Veterinary Medicine Advisory Board is a key step towards establishing a presence in the vibrant and expanding veterinary market.

Dr. Alice stated: "I am quite excited at the opportunity to work with AMI's team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as AMI’s Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."

Dr. Alice Villalobos is President Emeritus of the Society for Veterinary Medical Ethics, Past President of the American Association of Human Animal Bond Veterinarians and Chair of the Veterinary Academy for the National Academies of Practice. She operated Coast Pet Clinic/Animal Cancer Center for 25 years, which is now VCA Coast Animal Hospital. She is the author of numerous articles, papers, and including her classic veterinarian textbook, Canine and Feline Geriatric Oncology: Honoring the Human-Animal Bond. She has lectured worldwide on oncology, quality of life, the human-animal bond and end of life care and bioethics. She founded Pawspice, an end of life care program that embraces kinder, gentler palliative cancer medicine and integrative care for pets with cancer and terminal illness (www.Pawspice.com). Dr. Alice is Director of Animal Oncology Consultation Service in Woodland Hills, California and Pawspice at VCA Coast Animal Hospital in Hermosa Beach, California.

AMI Founder, CEO and Chairman James C. Katzaroff stated: "We are thrilled to have Dr. Alice join the Company as Chair of our newly formed Veterinary Medicine Advisory Board. She has demonstrated throughout her career her dedication to providing the best treatments available to pets affected by cancer. She has the knowledge, connections, influence and desire to be instrumental in bringing AMI’s brachytherapy products into the veterinary market."

The appointment of Dr. Alice to the Company's Veterinary Medicine Advisory Board follows AMI opening recruitment for the Company's first companion animal treatments through a study at Washington State University funded by the Washington State Life Sciences Discovery Fund for the treatment of feline sarcoma.

About Advanced Medical Isotope Corporation:

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.

Safe Harbor Statement:

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.


Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
1021 N Kellogg
Kennewick WA 99336

Investor Relations
Tyler M. Troup, B.Comm
Circadian Group IR, Managing Director

SOURCE: Advanced Medical Isotope Corporation